Related Experiment Video
Updated: Jun 3, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling
To Ha Loi1, Anna Campain, Adam Bryant
1Blood Stem Cell and Cancer Research Unit, Department of Haematology, St Vincent's Hospital, Victoria Street, Darlinghurst, Australia.
BMC Medical Genomics
|April 2, 2011
Summary
Gene expression profiling accurately differentiates lymphoma subtypes and reactive lymphadenopathy in lymph node biopsies. This approach could lead to a cost-effective, single-platform diagnostic mini-chip assay for faster results.
Area of Science:
- Oncology
- Molecular Diagnostics
- Bioinformatics
Background:
- Accurate diagnosis of lymphoma, a complex cancer, is crucial for effective patient management.
- Current diagnostic methods rely on multiple ancillary tests, including immunophenotyping, cytogenetics, and PCR, alongside histology.
- Gene expression microarray offers a potential single-platform solution for differential diagnosis.
Purpose of the Study:
- To evaluate gene expression microarray as a standalone diagnostic tool.
- To differentiate common lymphoma subtypes and reactive lymphadenopathy (RL) in lymph node biopsies.
- To assess the feasibility of a single-platform gene expression assay for lymphoma diagnosis.
Main Methods:
- 116 lymph node biopsies (RL, classical Hodgkin lymphoma (cHL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL)) were analyzed using mRNA microarray.
- Three supervised classification strategies (global multi-class, local binary-class, global binary-class) with diagonal linear discriminant analysis were employed.
- Classification error rates were calculated using leave-one-out cross-validation and tested on an independent dataset.
Main Results:
- Binary classifications achieved prediction accuracies of 88.5% for FL, 82.8% for cHL, 82.8% for DLBCL, and 80.0% for RL.
- Specific gene classifiers were identified: LIM domain only-2 (LMO2) for FL, Chemokine (C-C motif) ligand 22 (CCL22) for cHL, and Cyclin-dependent kinase inhibitor-3 (CDK3) for DLBCL.
- The study demonstrated the potential of gene expression profiling in classifying major lymphoma subtypes.
Conclusions:
- Gene expression profiling effectively distinguishes lymphoma from reactive conditions and classifies major lymphoma subtypes within a diagnostic context.
- A cost-effective, single-platform "mini-chip" assay could be developed to expedite lymph node biopsy diagnosis.
- This approach has the potential to be expanded to include other pathological entities.
